Wednesday, July 8, 2026

pharma · Advanced Solid Tumor · Sarcoma · PRLD

Prelude Therapeutics

Prelude Therapeutics clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

175 Innovation Boulevard, Wilmington, DE 19805, US HQ
2016 Founded
111 Employees
Public company Type
PRLD · NYSE Ticker
Company details
Status
Public
HQ
175 Innovation Boulevard, Wilmington, DE 19805, US
Founded
2016
Employees
111
Programs
13
Drugs
5
Patents
16
Intelligence · Clinical Programs

Prelude Therapeutics projects

11 ClinicalTrials.gov programs sponsored by Prelude Therapeutics.

Prelude Therapeutics has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PRT12396

    Prelude Therapeutics Inc

    Polycythemia Vera (PV)

    phase 1 small molecule active

    1 trial
  2. PRT1419

    Prelude Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial
  3. PRT1419

    Prelude Therapeutics Inc

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial
  4. PRT1419

    Prelude Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial
  5. PRT2527

    Prelude Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial
  6. PRT2527

    Prelude Therapeutics Inc

    Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial
  7. PRT3645

    Prelude Therapeutics Inc

    Breast Cancer

    phase 1 small molecule completed

    1 trial
  8. PRT543

    Prelude Therapeutics Inc

    Relapsed/Refractory Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  9. PRT7732

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial
  10. PRT7732-01

    Prelude Therapeutics Inc

    esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 1 other active

    1 trial
  11. PRT811

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Prelude Therapeutics have?

11 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.